# 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

> **NCT06104228** · PHASE2 · RECRUITING · sponsor: **Bastiaan Driehuys** · enrollment: 20 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Arterial Hypertension
- Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)
- Connective Tissue Diseases

## Interventions

- **DRUG:** 129Xe Hyperpolarized

## Key facts

- **NCT ID:** NCT06104228
- **Lead sponsor:** Bastiaan Driehuys
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-12
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06104228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06104228, "129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06104228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*